STNhjuyiuy

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 3	JAN 25	Annual Reload of MEDLINE database
NEWS 4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS 9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS 11	APR 02	DWPI: New display format ALLSTR available
NEWS 12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 14	APR 07	CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS 15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS 16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial

Updated Search

gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:26:48 ON 01 JUN 2010

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 15:26:57 ON 01 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAY 2010 HIGHEST RN 1226488-46-5
DICTIONARY FILE UPDATES: 31 MAY 2010 HIGHEST RN 1226488-46-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red Folder\adfafafafaf.str

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 15:30:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 257371 TO ITERATE

0.8% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 5117662 TO 5177178
PROJECTED ANSWERS: 0 TO 0

STNhjuyiuy

```
L2            0 SEA SSS SAM L1

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red
Folder\adfasfafafaf.str

L3      STRUCTURE UPLOADED

=> s l3
SAMPLE SEARCH INITIATED 15:31:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7303 TO ITERATE

 27.4% PROCESSED     2000 ITERATIONS                                 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       140936 TO   151184
PROJECTED ANSWERS:              63 TO      521

L4            4 SEA SSS SAM L3

=> s l3 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:31:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   147332 TO ITERATE

100.0% PROCESSED   147332 ITERATIONS                             537 ANSWERS
SEARCH TIME: 00.00.13

L5          537 SEA SSS FUL L3

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              195.46     195.68

FILE 'HCAPLUS' ENTERED AT 15:32:10 ON 01 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.
```

STNhjuyiuy

FILE COVERS 1907 - 1 Jun 2010 VOL 152 ISS 23
FILE LAST UPDATED: 31 May 2010 (20100531/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L6 40 L5

=> s l6 and bold, g?/au
109 BOLD, G?/AU
L7 5 L6 AND BOLD, G?/AU

=> d l7, ibib abs fhitstr, 1-5
THE ESTIMATED COST FOR THIS REQUEST IS 29.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L7 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:515506 HCAPLUS
DOCUMENT NUMBER: 141:71453
TITLE: Preparation of anthranilic acid amide derivatives as neoplastic inhibitors
INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052884	A1	20040624	WO 2003-EP14086	20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2506164	A1	20040624	CA 2003-2506164	20031211
AU 2003294834	A1	20040630	AU 2003-294834	20031211
EP 1572686	A1	20050914	EP 2003-785795	20031211

Updated Search

EP 1572686		B1	20090415			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
BR 2003017292		A	20051108	BR 2003-17292		20031211
CN 1720244		A	20060111	CN 2003-80104845		20031211
CN 100427483		C	20081022			
JP 2006511518		T	20060406	JP 2004-558075		20031211
AT 428709		T	20090515	AT 2003-785795		20031211
PT 1572686		E	20090714	PT 2003-785795		20031211
ES 2324531		T3	20090810	ES 2003-785795		20031211
US 20060128684		A1	20060615	US 2005-538199		20050609
PRIORITY APPLN. INFO.:				GB 2002-29022	A	20021212
				WO 2003-EP14086	W	20031211

OTHER SOURCE(S): MARPAT 141:71453

GI



AB The title compds. I [wherein R and R0 = independently H, halo, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.; R1 = H, halo, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, OCF3, OCH2CF3, OCH2CH2CF3, or OCH2CH2CH2CF3; R2 = perfluoroalkyl; R3 = H or halo; X = OH, alkoxy, alkylthio, imino, alkylimino, halo, etc.; Z = N or CH] or salts, N-oxides, or tautomers thereof are prepared as neoplastic inhibitors for the treatment of human or animal body. For example, the compound II was prepared in a multi-step synthesis. Formulations containing I as an active ingredient were also described.

IT 1055921-40-8
RL: PRPH (Prophetic)
(Preparation of anthranilic acid amide derivatives as neoplastic inhibitors)

RN 1055921-40-8 HCAPLUS

CN Benzamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-[(4-methyl-1-piperazinyl)methyl]-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)

STNhjuyiuy



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:376825 HCAPLUS
DOCUMENT NUMBER: 138:385308
TITLE: Preparation of anthranilic acid amides and their use as vascular endothelial growth factor receptor tyrosine kinase inhibitors
INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma Gmbh
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040102	A1	20030515	WO 2002-EP12444	20021107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
TW 260222	B	20060821	TW 2002-91132669	20021106
CA 2463968	A1	20030515	CA 2002-2463968	20021107
AU 2002351909	A1	20030519	AU 2002-351909	20021107
AU 2002351909	B2	20070426		
EP 1446382	A1	20040818	EP 2002-787595	20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013970	A	20040831	BR 2002-13970	20021107
CN 1585750	A	20050223	CN 2002-822209	20021107

Updated Search

CN 1300113	C	20070214			
JP 2005511602	T	20050428	JP 2003-542148		20021107
NZ 532590	A	20051223	NZ 2002-532590		20021107
RU 2318811	C2	20080310	RU 2004-117543		20021107
ZA 2004002940	A	20050210	ZA 2004-2940		20040419
US 20050096356	A1	20050505	US 2004-494591		20040505
US 7091224	B2	20060815			
IN 2004CN00972	A	20060203	IN 2004-CN972		20040506
HR 2004000411	A2	20050430	HR 2004-411		20040507
NO 2004002187	A	20040526	NO 2004-2187		20040526
NO 327231	B1	20090518			
US 20060178409	A1	20060810	US 2006-374720		20060314
US 7482369	B2	20090127			
PRIORITY APPLN. INFO.:			GB 2001-26902	A	20011108
			WO 2002-EP12444	W	20021107
			US 2004-494591	A1	20040505

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:385308
GI



I

AB Anthranilic acid amide derivs. [I; R1, R2 = H, lower alkyl; R3 = lower perfluoroalkyl; X = O, S; e.g., 2-[(6-Methoxy-3-pyridinyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide hydrochloride, m.p. 133-135°], which are vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of neoplastic disease, of retinopathy or age-related macular degeneration, are prepared and a I-containing formulation presented (e.g., a soft capsule).

IT 524941-34-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of anthranilic acid amides)

RN 524941-34-2 HCAPLUS

CN Benzamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-(2-propyn-1-yl)-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:376824 HCAPLUS
DOCUMENT NUMBER: 138:368777
TITLE: Preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease
INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma Gmbh
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040101	A1	20030515	WO 2002-EP12445	20021107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
TW 260985	B	20060901	TW 2002-91132668	20021106
CA 2462390	A1	20030515	CA 2002-2462390	20021107
AU 2002342889	A1	20030519	AU 2002-342889	20021107
AU 2002342889	B2	20070301		
EP 1446381	A1	20040818	EP 2002-779536	20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013939	A	20040831	BR 2002-13939	20021107
CN 1578768	A	20050209	CN 2002-821430	20021107
CN 100467450	C	20090311		
JP 2005508382	T	20050331	JP 2003-542147	20021107
JP 4179989	B2	20081112		
NZ 532587	A	20060224	NZ 2002-532587	20021107
NZ 543915	A	20070629	NZ 2002-543915	20021107
RU 2315756	C2	20080127	RU 2004-117548	20021107

US 20040248947	A1	20041209	US 2004-494222		20040503
US 7067543	B2	20060627			
IN 2004CN00973	A	20060203	IN 2004-CN973		20040506
MX 2004004390	A	20050516	MX 2004-4390		20040507
HR 2004000412	A2	20050630	HR 2004-412		20040507
NO 2004002137	A	20040525	NO 2004-2137		20040525
NO 326986	B1	20090330			
ZA 2004002623	A	20060531	ZA 2004-2623		20060328
PRIORITY APPLN. INFO.:			GB 2001-26901	A	20011108
			GB 2002-12917	A	20020605
			NZ 2002-532587	A3	20021107
			WO 2002-EP12445	W	20021107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:368777
GI



I



II

AB The title compds. [I; Ar = II (wherein Ra = H, alkyl; and R1 = H, perfluoroalkyl; R2 = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R1 = perfluoroalkyl; R2 = Br, I, alkyl, alkenyl, alkynyl; or R1 = H, and R2 = F, Br, I, Et, alkyl, alkenyl or alkynyl] and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4-pyridinecarboxaldehyde with 2-amino-N-(4-bromo-3-trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH3CN afforded I [Ar = 4-pyridyl; R1 = CF3; R2 = Br]. The IC50-values that can be found for the compds. I are in range of 0.001 to 1 μM in test for activity against VEGF-receptor tyrosine kinase.

IT 524728-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)

RN 524728-97-0 HCAPLUS

CN Benzamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[[(6-methoxy-3-pyridinyl)methyl]amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:565010 HCAPLUS
DOCUMENT NUMBER: 135:137407
TITLE: Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors
INVENTOR(S): Manley, Paul William; Bold, Guido
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055114	A1	20010802	WO 2001-EP835	20010125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2396590	A1	20010802	CA 2001-2396590	20010125
AU 2001028499	A	20010807	AU 2001-28499	20010125
AU 771626	B2	20040401		
BR 2001007805	A	20021022	BR 2001-7805	20010125
EP 1259487	A1	20021127	EP 2001-946854	20010125
EP 1259487	B1	20091223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002004083	A2	20030328	HU 2002-4083	20010125
HU 2002004083	A3	20050329		
JP 2003520853	T	20030708	JP 2001-555056	20010125
JP 3894793	B2	20070322		
NZ 520005	A	20040227	NZ 2001-520005	20010125

	CN 1216867	C	20050831	CN 2001-804233	20010125
	RU 2296124	C2	20070327	RU 2002-121645	20010125
	IL 150481	A	20090922	IL 2001-150481	20010125
	AT 452880	T	20100115	AT 2001-946854	20010125
	PT 1259487	E	20100326	PT 2001-946854	20010125
	EP 2168948	A1	20100331	EP 2009-179064	20010125
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, RO, SI				
	ES 2338407	T3	20100507	ES 2001-946854	20010125
	NO 2002003218	A	20020916	NO 2002-3218	20020702
	NO 323826	B1	20070709		
	US 20030032656	A1	20030213	US 2002-181005	20020711
	US 6624174	B2	20030923		
	MX 2002007319	A	20021129	MX 2002-7319	20020726
	ZA 2002005988	A	20030728	ZA 2002-5988	20020726
	IN 224652	A1	20081205	IN 2002-CN1150	20020726
	HK 1050895	A1	20051230	HK 2003-103030	20030429
PRIORITY APPLN. INFO.:				GB 2000-1930 A	20000127
				EP 2001-946854 A3	20010125
				WO 2001-EP835 W	20010125

OTHER SOURCE(S): MARPAT 135:137407
GI



AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepared and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].

IT 352227-59-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)

RN 352227-59-9 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[3-

(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:335388 HCAPLUS
DOCUMENT NUMBER: 132:347491
TITLE: Preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors
INVENTOR(S): Altmann, Karl-Heinz; Bold, Guido; Furet, Pascal; Manley, Paul William; Wood, Jeanette Marjorie; Ferrari, Stefano; Hofmann, Francesco; Mestan, Jurgen; Huth, Andreas; Kruger, Martin; Seidelmann, Dieter; Menrad, Andreas; Haberey, Martin; Thierauch, Karl-Heinz
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Schering Aktiengesellschaft
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027820	A1	20000518	WO 1999-EP8545	19991108

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2346898	A1	20000518	CA 1999-2346898		19991108
BR 9915210	A	20010724	BR 1999-15210		19991108
TR 2001001237	T2	20010821	TR 2001-1237		19991108
EP 1129075	A1	20010905	EP 1999-971802		19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
HU 2001004188	A2	20020328	HU 2001-4188		19991108
HU 2001004188	A3	20020429			
JP 2002529453	T	20020910	JP 2000-581000		19991108
AU 758230	B2	20030320	AU 2000-13811		19991108
NZ 511339	A	20030725	NZ 1999-511339		19991108
CN 1152014	C	20040602	CN 1999-813108		19991108
RU 2286338	C2	20061027	RU 2001-114978		19991108
CZ 299829	B6	20081210	CZ 2001-1615		19991108
SK 287259	B6	20100407	SK 2001-628		19991108
NO 2001001894	A	20010704	NO 2001-1894		20010417
NO 328130	B1	20091214			
ZA 2001003290	A	20030123	ZA 2001-3290		20010423
MX 2001004256	A	20030606	MX 2001-4256		20010427
US 20020019414	A1	20020214	US 2001-850434		20010507
US 6448277	B2	20020910			
IN 2001CN00638	A	20050304	IN 2001-CN638		20010508
ZA 2001004673	A	20020909	ZA 2001-4673		20010607
US 20030064992	A1	20030403	US 2002-180289		20020626
US 6878720	B2	20050412			
US 20040198782	A1	20041007	US 2004-828951		20040421
US 7002022	B2	20060221			
US 20060074112	A1	20060406	US 2005-254897		20051020
PRIORITY APPLN. INFO.:			GB 1998-24579	A	19981110
			WO 1999-EP8545	W	19991108
			US 2001-850434	A3	20010507
			US 2002-180289	A3	20020626
			US 2004-828951	A3	20040421

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 132:347491
GI



I

AB Use of title compds. I; W = O, S; X = NR8; Y = CR9R10(CH2)n, SO2; R9, R10 = H, alkyl; n = 0-3; R1 = aryl; R2 = mono- or bicyclic heteroaryl with the exception that R2 cannot = 2-phthalimidyl, and when Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; R3-R6 = H, substituent; R7, R8 = H, alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine

kinase activity is claimed. Thus, a mixture of 4-pyridinecarboxaldehyde and 2-amino-N-(4-trifluoromethylphenyl)benzamide (preparation given) in MeOH containing
HOAc was treated with NaBH3CN followed by 16 h stirring to give 2-[(4-pyridyl)methyl]amino-N-[4-(trifluoromethyl)phenyl]benzamide. Tested I inhibited Flt-1 VEGF receptor tyrosine kinase with IC50 = 0.18-0.56 μM.

IT 269391-00-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors)

RN 269391-00-6 HCAPLUS

CN Benzamide, 2-[[(2-methyl-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 38 THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (42 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT